Acadia Pharmaceuticals Inc.

Niels Skjaerbaek

Bo-Ragnar Tolf

Kristian Norup Koch

Bo Lennart Mikael Friberg

Tracy Spalding

Mark R Brann

Allan K Uldam

Erika Currier

Kate Duggento

Mikael Friberg

Bo Lennart M Friberg

Terri Messier

Carl-Magnus A Andersson

Carl-Magnus A Anderson

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

Tetrahydroquinoline analogues as muscarinic agonists

Muscarinic agonists

Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

Compounds with activity on muscarinic receptors

Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Growing community of inventors

Vedbaek, Denmark

Niels Skjaerbaek